Companies: 10,795·Total market cap: $144.5T

Ascentage Pharma Group International

Ascentage Pharma Group International

ASPHFOTCHealthcare● Active

$4.53

$-0.17(-3.51%)

Market Cap$1.7B

P/E Ratio—

52W High$10.65

52W Low$4.53

Avg Volume3

Open$4.53

Beta0.65

Net Income Financials Revenue

Ascentage Pharma Group International (ASPHF) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

ASPHF · net income · updated Jun 8, 2026

Core profitability metrics

ASPHF · net income · margin · TTM · CAGR

Net income was −$1.21B for FY2025 (fiscal year ending 2025-12-31), down 198.6% year-over-year. Net profit margin was -216.5%.

FY2025 Net Income−$1.21B▼ -198.6% YoY

Trailing 12M (TTM)−$1.13Btrailing 4 quarters sum

Net Profit Margin-216.5%−$1.21B ÷ $559.3M

YoY Change-198.6%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · ASPHF net income history · ASPHF profit margin

Annual net income data

ASPHF · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$1.21B▼ 198.6%-216.5%$559.3M

FY2024Loss−$405.4M▲ +56.2%-41.3%$980.6M

FY2023Loss−$925.6M▼ 4.8%-417.0%$222.0M

FY2022Loss−$882.9M▼ 12.8%-421.0%$209.7M

FY2021Loss−$782.4M▼ 15.5%-2803.4%$27.9M

Net income vs peers (Healthcare)

ASPHF vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Ascentage Pharma Group InternationalYOU

ASPHF

−$1.21B-198.6%-216.5%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Ascentage Pharma Group International (ASPHF) reported net income of −$1.21B for FY2025 (fiscal year ending 2025-12-31), down 198.6% year-over-year. The net profit margin was -216.5% — meaning the company kept $-2.16 of every dollar of revenue as profit.

Ascentage Pharma Group International has not yet achieved annual profitability based on available data (10 fiscal years). The company has reported net losses across all available periods.

Ascentage Pharma Group International's net profit margin was -216.5% for FY2025, based on the latest annual results.

Investors sometimes search for "Ascentage Pharma Group International net worth" — the company's market capitalization is a separate figure from ASPHF net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

ASPHF net income · 4 questions

Ascentage Pharma Group International is not currently profitable on an annual basis. The company reported a net loss of $1.21B for FY2025.

is ASPHF profitabledoes ASPHF make a profitASPHF profitabilityASPHF profitable company

▸ Source: FMP /income-statement · GAAP · Ascentage Pharma Group International · Ascentage Pharma Group International SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026